Merus BV (MRUS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Merus BV (MRUS) has a cash flow conversion efficiency ratio of -0.128x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-84.92 Million) by net assets ($661.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Merus BV to measure how much of total assets are equity-financed.
Merus BV - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Merus BV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Merus BV cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Merus BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Merus BV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
InterDigital Inc
NASDAQ:IDCC
|
0.015x |
|
United Integrated Services Co Ltd
TW:2404
|
0.448x |
|
The Swatch Group AG
F:UHRA
|
0.012x |
|
Shenzhen Capchem Tech
SHE:300037
|
0.021x |
|
Bank Millennium S.A.
WAR:MIL
|
0.199x |
|
Hellenic Telecommunications Organization S.A
AT:HTO
|
0.117x |
|
National Aluminium Company Limited
NSE:NATIONALUM
|
0.126x |
|
Qingdao Port International Co Ltd
SHG:601298
|
0.031x |
Annual Cash Flow Conversion Efficiency for Merus BV (2013–2024)
The table below shows the annual cash flow conversion efficiency of Merus BV from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see MRUS stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $650.36 Million | $-185.84 Million | -0.286x | +28.40% |
| 2023-12-31 | $356.34 Million | $-142.21 Million | -0.399x | +34.23% |
| 2022-12-31 | $247.06 Million | $-149.90 Million | -0.607x | -221.76% |
| 2021-12-31 | $316.20 Million | $-59.63 Million | -0.189x | +75.87% |
| 2020-12-31 | $102.26 Million | $-79.90 Million | -0.781x | -62.71% |
| 2019-12-31 | $131.30 Million | $-63.05 Million | -0.480x | -8.93% |
| 2018-12-31 | $105.09 Million | $-46.33 Million | -0.441x | +43.58% |
| 2017-12-31 | $57.45 Million | $-44.88 Million | -0.781x | -3.32% |
| 2016-12-31 | $35.79 Million | $-27.06 Million | -0.756x | +7.08% |
| 2015-12-31 | $30.94 Million | $-25.18 Million | -0.814x | -119.85% |
| 2014-12-31 | $-4.33 Million | $-17.74 Million | 4.099x | +551.01% |
| 2013-12-31 | $10.58 Million | $-9.62 Million | -0.909x | -- |
About Merus BV
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the… Read more